IGF-1 LR3 (1mg Vial) Dosage Protocol
Long-acting IGF-1 analog studied for anabolic effects — research/educational dosing reference.
Mix & measure IGF-1 LR3 · 1 mg
Pre-filled with this protocol’s recommended BAC water and documented starting dose — edit any field to run your own numbers.
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Full reconstitution guide → · Advanced calculator →
Quickstart Highlights
IGF-1 LR3 (Long-Arg3 Insulin-like Growth Factor-1) is a modified analog of human IGF-1 with much-reduced affinity for IGF binding proteins, giving it a substantially longer half-life and prolonged receptor activity[1][2]. This educational page outlines a once-daily subcutaneous approach with a dilution chosen so doses land on easy-to-read insulin-syringe marks. It is an unapproved research chemical, not a medicine, and human efficacy and safety for the touted anabolic uses are not established — presented for research and educational use only.
Add 3.0 mL bacteriostatic water to one 1 mg vial → ~0.333 mg/mL (333 mcg/mL), a large dilution chosen for accurate low-dose measuring.
20–50 mcg once daily subcutaneously, titrated upward gradually across an 8–12 week course.
At ~0.333 mg/mL, 1 unit ≈ 3.33 mcg; 20 mcg ≈ 6 units and 50 mcg ≈ 15 units on a U-100 syringe.
Lyophilized: store at −20 °C (−4 °F); once reconstituted, refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze the solution.
Important: Start with the Prep & Injection Guide — it covers the preparation and safety basics every protocol on this site assumes.
Dosing & Reconstitution Guide
A single practical dilution with accurate once-daily dosing, step by step
Standard / Gradual Approach (3 mL = ~0.333 mg/mL)
Reconstitute: Add 3.0 mL bacteriostatic water to one 1 mg vial → final concentration ~0.333 mg/mL (333 mcg/mL).
Typical daily range: 20–50 mcg once daily subcutaneously, raised gradually over an 8–12 week course.
Easy measuring: At ~0.333 mg/mL, 1 unit ≈ 3.33 mcg on a U-100 syringe (1 unit = 0.01 mL). For doses at or below 10 units, a 30- or 50-unit syringe improves readability.
Storage: Lyophilized: store at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze the mixed solution.
Frequency: one subcutaneous injection each day, typically in the morning or post-workout with food to blunt insulin-like effects on blood glucose[3]. Conservative research protocols stay at or below 50 mcg/day. These figures come from reference protocols, not from approved human dosing.
Reconstitution Steps
Draw 3.0 mL of bacteriostatic water into a sterile syringe.
Release it slowly down the vial’s inner wall to limit foaming.
Swirl or roll gently until fully dissolved — don’t shake.
Label with the date and concentration, then refrigerate at 2–8 °C (35.6–46.4 °F), shielded from light.
The 3.0 mL dilution is deliberately large so low microgram doses read on clear U-100 markings. Avoid freezing the reconstituted solution, since freeze–thaw can denature the peptide.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Supplies Needed
Quantities below assume an 8–16 week course of once-daily injections with gradual titration.
At 20–50 mcg/day, one 1 mg vial covers roughly two to three weeks; plan a few vials per cycle.
- 8 weeks: ~3 vials (~2.24 mg)
- 12 weeks: ~4 vials (~3.64 mg)
- 16 weeks: ~6 vials (~5.04 mg)
- Per injection: 1 syringe
- 8 weeks (once daily): ~56 syringes
- 16 weeks (once daily): ~112 syringes
Use 3.0 mL per 1 mg vial for reconstitution.
- 8 weeks (3 vials): ~9 mL → 1 bottle
- 16 weeks (6 vials): ~18 mL → 2 bottles
One for the vial stopper + one for the injection site each day.
- Per injection: 2 swabs
- 8 weeks (once daily): ~112 swabs → 1–2 boxes
Protocol Overview
A concise summary of the once-daily subcutaneous regimen, drawn from commonly cited reference protocols.
- ▪Goal: Explore anabolic and metabolic effects driven by sustained IGF-1 receptor activity from this long-acting analog — effects studied preclinically and not established in humans[1][2].
- ▪Schedule: Daily subcutaneous injections for 8 weeks (standard cycle); may extend to 12 weeks with appropriate off-periods.
- ▪Dose Range: 20–50 mcg per day with gradual titration; conservative protocols remain at or below 50 mcg/day.
- ▪Reconstitution: 3.0 mL bacteriostatic water per 1 mg vial gives ~0.333 mg/mL (333 mcg/mL) for precise unit measurements.
- ▪Storage: Keep the dry vial frozen at −20 °C (−4 °F); once mixed, refrigerate at 2–8 °C and do not freeze the solution.
- ▪Cycling: A common approach is 8 weeks on, 4–8 weeks off to limit receptor desensitization.
Dosing Protocol
A suggested daily titration approach for tolerance assessment.
- ▪Start (Weeks 1–2): 20 mcg once daily to assess tolerance, particularly any effect on blood glucose.
- ▪Titrate (Weeks 3–4): Increase to 40 mcg daily if the first two weeks are well tolerated with no significant hypoglycemic symptoms.
- ▪Maintain (Weeks 5–8): Hold at 50 mcg daily; this is the conservative upper end for most research protocols.
- ▪Frequency & timing: Once per day subcutaneously, often aligned with meals (morning or post-workout) to manage insulin-like effects.
- ▪Cycle Length: 8 weeks is standard; 12-week protocols exist but may show diminishing returns.
- ▪Site Rotation: Rotate injection sites systematically (abdomen, thighs, upper arms) to prevent local irritation or lipohypertrophy.
Storage Instructions
Correct storage is what preserves the peptide’s stability and potency.
- ▪Lyophilized: Hold the dry vial at −20 °C (−4 °F) or colder in dry, dark conditions for up to 12 months[7].
- ▪Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F) and use within about 30 days; do not freeze the mixed solution, as freezing can denature peptides[8].
- ▪Handling: Let frozen vials warm to room temperature before opening so condensation won’t form, and keep the solution clear of heat and direct light.
- ▪Freeze–thaw: Avoid repeated freeze–thaw cycles of the reconstituted solution; for longer storage, prepare aliquots and freeze.
Important Notes
Practical points that keep daily administration safe and consistent.
- ▪Blood-glucose caution: IGF-1 LR3 has insulin-like activity and can lower blood sugar; keep a fast-acting carbohydrate (glucose tablets or juice) on hand and watch for hypoglycemia, especially during titration[6].
- ▪Sterile technique: Use a fresh sterile U-100 insulin syringe each time and drop it straight into a puncture-proof sharps container afterward.
- ▪Site rotation: Move between abdomen, thighs and upper arms to reduce local irritation and lipohypertrophy[9].
- ▪Recordkeeping: Log the daily dose, injection site and any observations to keep the protocol consistent.
- ▪Regulatory note: IGF-1 LR3 is not approved by any regulator for human use and is prohibited in sport; it is sold strictly “for research use only.”
How This Works
IGF-1 LR3 (Long-Arg3 IGF-1) is a modified analog of insulin-like growth factor-1. It adds a 13-amino-acid extension at the N-terminus and substitutes arginine for glutamic acid at position 3, which sharply reduces its binding to IGF binding proteins[1][2].
Because it is largely free of those binding proteins, the analog stays active far longer than native IGF-1 — a substantially extended half-life and more sustained systemic exposure. It works by activating the IGF-1 receptor, a tyrosine-kinase receptor that drives cell growth, proliferation and protein synthesis, which is why it is studied for anabolic and muscle-related effects.
Through this receptor it also shares insulin-like metabolic activity, including increased glucose uptake, which is the basis for its hypoglycemia risk.
Important caveat: the anabolic and physique claims around IGF-1 LR3 rest largely on cell-culture and animal work plus anecdote; human efficacy and safety for these uses are not established. Because IGF-1 signalling promotes cell proliferation, a recognized theoretical concern is that it could promote the growth of existing tumors, and excess dosing can cause hypoglycemia.
IGF-1 LR3 is not an approved medicine. It is an unapproved research chemical presented here for research and educational purposes only.
Lifestyle Factors
Habits that may support results alongside the protocol.
- ▪Nutrition: Keep protein and overall calorie intake adequate to give protein synthesis the building blocks it needs.
- ▪Activity & rest: Pair appropriate training with real recovery time and avoid overtraining.
- ▪Sleep: Aim for 7–9 hours to support the body’s natural growth and repair processes.
- ▪Blood sugar: Eat around injection time and keep fast-acting carbohydrate available, since IGF-1 LR3 can lower blood glucose.
Potential Benefits & Side Effects
What preclinical literature describes; human evidence is limited and individual results vary.
Potential Benefits
- ▪Anabolic signalling (preclinical): Cell and animal studies report increased cell growth and protein synthesis via IGF-1 receptor activation[1].
- ▪Extended activity: Reduced binding-protein affinity gives a longer half-life than native IGF-1, the analog’s defining feature[2].
- ▪Note on humans: These effects are not established in humans — no completed clinical efficacy trials support the touted physique uses.
Risks & Side Effects
- ▪Hypoglycemia: Insulin-like activity can drop blood sugar; symptoms include shakiness, sweating, confusion. Keep fast-acting carbohydrate on hand[6].
- ▪Tumor-growth concern: Because IGF-1 signalling promotes cell proliferation, there is a theoretical concern it could promote growth of existing tumors.
- ▪Injection-site reactions: Mild redness, tenderness or soreness can occur; rotating sites helps.
- ▪Unknown long-term profile: Human safety data is limited; it is not approved by any regulator and is restricted in sport.
Injection Technique
General subcutaneous technique, following established clinical best-practice guidance[14][15].
Pre-Injection Preparation
- ▪Wash your hands well with soap and water.
- ▪Wipe the vial stopper with an alcohol swab and let it air-dry.
- ▪Choose a site (abdomen, thigh, or upper arm) and clean it with a fresh alcohol swab, letting it dry fully[15].
- ▪Draw the intended dose, then check for air bubbles and push any out.
Injection Procedure
- ▪Pinch a skinfold at the chosen site between thumb and forefinger.
- ▪Insert the needle into the pinch at a 45–90-degree angle (use 45 degrees if the fat layer is thin)[14].
- ▪Skip aspiration for subcutaneous shots — it isn’t needed[14].
- ▪Press the plunger slowly and steadily until it’s fully down.
- ▪Wait 5–10 seconds, then pull the needle straight out to prevent leakage.
Post-Injection Care
- ▪Drop the used syringe straight into a puncture-proof sharps container — never recap a needle.
- ▪Return the reconstituted vial to the fridge right away.
- ▪Rotate the injection site each day to prevent irritation and lipohypertrophy[9].
- ▪Watch the site for excess redness, swelling, or signs of infection.
Recommended Source
For high-purity research peptides, we point researchers to Prime Lab Peptides.
Why Prime Lab Peptides?
- ▪Top-rated on Trustpilot: Independently reviewed as the highest-rated peptide lab on Trustpilot — making it the best current source in the USA.
- ▪Third-party tested: Every batch ships with a Certificate of Analysis (COA) confirming purity and composition.
- ▪Consistent quality: ISO-aligned manufacturing and handling keep product integrity reliable batch to batch.
- ▪Cold-chain integrity: Temperature-controlled shipping and storage across the whole fulfilment chain.
- ▪Research-grade purity: Fit for educational and research use that demands high-quality peptides.
Note: Product availability and specifications subject to change. Verify current product details on the supplier website.
References
- 1
Growth Hormone & IGF ResearchLong-Arg3-IGF-1: structure, reduced IGF binding-protein affinity, and extended biological activity of the analog.
- 2
Journal of Biological Chemistry (PubMed)Reduced binding-protein affinity and enhanced potency of N-terminally extended IGF-1 analogs.
- 3
Endocrinology / Metabolism ReviewIGF-1 receptor signalling, insulin-like metabolic effects and glucose handling.
- 4
Peptide Storage GuideBest practices for storing lyophilized peptides (temperature, humidity and light protection).
- 5
Bacteriostatic Water GuidanceBacteriostatic water for injection: multi-dose vial stability and handling.
- 6
Hypoglycemia (StatPearls / NCBI)Recognition and management of hypoglycemia, including symptoms and rapid-carbohydrate treatment.
- 7
Peptide Storage GuideLong-term storage of lyophilized peptides and reconstituted solutions.
- 8
Bacteriostatic Water GuidanceReconstituted peptide stability: refrigeration and avoidance of freeze-thaw.
- 9
NCBI BookshelfBest practices for subcutaneous injection: aseptic technique and site rotation.
- 10
IGF-1 and Cancer Risk (PubMed)Reviews of IGF-1 signalling and its association with proliferation and tumor growth.
- 11
WADA Prohibited ListIGF-1 and its analogs are prohibited substances in competitive sport (S2 peptide hormones / growth factors).
- 12
FDA Drug InformationIGF-1 LR3 is not an approved drug; unapproved research chemicals are not evaluated for human safety or efficacy.
- 13
ClinicalTrials.govTrial registry searches for IGF-1 analogs; no completed efficacy trials support the touted physique uses of IGF-1 LR3.
- 14
Centers for Disease Control and Prevention (CDC)Subcutaneous injection technique: angle, site and no-aspiration guidance.
- 15
Subcutaneous Injection Technique (Patient Education)How to administer a subcutaneous injection: clinical technique guidelines.
- 16
Prime Lab PeptidesResearch peptide supplier — purity specifications and certificates of analysis.
How to reconstitute IGF-1 LR3
- 1Wipe the vial stopper and your bacteriostatic-water vial with an alcohol swab.
- 2Draw your chosen amount of bacteriostatic water and inject it slowly down the inner wall of the IGF-1 LR3 vial.
- 3Let it rest, then gently swirl until fully dissolved — do not shake.
- 4Refrigerate the reconstituted vial and draw each dose with a U-100 insulin syringe.
IGF-1 LR3 — frequently asked questions
How do I reconstitute a 1 mg vial of IGF-1 LR3?
Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units.
How much bacteriostatic water should I add to IGF-1 LR3?
There is no single correct amount — more water simply spreads the same 1 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units.
What do the "units" on an insulin syringe mean?
On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand.
How should I store IGF-1 LR3 after mixing?
Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product.
How many doses does a 1 mg vial of IGF-1 LR3 provide?
Divide the vial strength of 1 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose.
Is IGF-1 LR3 approved for human use?
No. IGF-1 LR3 is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.
New protocols & dosing updates
Reconstitution charts, new peptide protocols and safety updates — straight to your inbox. No spam, unsubscribe anytime.